Hiroki Hidejima
Director/Board Member bei METAREAL CORPORATION
Vermögen: 2 Mio $ am 31.03.2024
Profil
Hiroki Hidejima is currently a Director at several companies including HuBit Genomix KK, THANN Natural KK, BioComo, Inc., C.H.C.
SYSTEM Co., Ltd., and Development Association For Youthleaders.
He is also an Outside Director at Metareal Corp.
and an Auditor at YES-fm KK.
He received his undergraduate degree from Kobe University Graduate School of Business Administration in 1973.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
METAREAL CORP.
1,93% | 31.08.2023 | 207 500 ( 1,93% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Hiroki Hidejima
Unternehmen | Position | Beginn |
---|---|---|
METAREAL CORPORATION | Director/Board Member | 01.04.2004 |
J & I YK | Director/Board Member | 01.02.2004 |
YES-fm KK | Comptroller/Controller/Auditor | 01.03.2005 |
C.H.C. SYSTEM Co., Ltd. | Director/Board Member | 01.05.2005 |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Director/Board Member | 01.07.2010 |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Director/Board Member | 01.06.2014 |
THANN Natural KK | Director/Board Member | 01.06.2012 |
Development Association For Youthleaders | Director/Board Member | 01.03.2004 |
Ausbildung von Hiroki Hidejima
Kobe University Graduate School of Business Administration | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
METAREAL CORPORATION | Technology Services |
Private Unternehmen | 7 |
---|---|
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Commercial Services |
C.H.C. SYSTEM Co., Ltd. | |
THANN Natural KK | |
J & I YK | |
YES-fm KK | |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Health Technology |
Development Association For Youthleaders |